(Q33834424)

English

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

macular degeneration

1 reference

based on heuristic

inferred from title

author name string

Charles C Wykoff

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David M Brown

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Maria E Maldonado

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel E Croft

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

11 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

British Journal of Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

951-955

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078682

4 July 2018

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304736

21 January 2018

Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304736

21 January 2018

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304736

21 January 2018

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304736

21 January 2018

Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2013-304736

21 January 2018

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24518078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24518078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24518078

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BJOPHTHALMOL-2013-304736

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33834424&oldid=1533523767"